Zoetis Sheds a Quarter of Its Value as US Pet Owners Skip Vet Visits

Zoetis shares hit 52-week low after slashing forecast as cost-conscious US pet owners defer vet care; Elanco gains market share.

Zoetis shareholders endured a brutal week as the animal health giant’s shares crashed nearly 27 percent, hitting a fresh 52-week low of €70.48 on Friday. The rout came after management slashed its full-year outlook, revealing that cost-conscious American pet owners are deferring veterinary care far more aggressively than anticipated.

The first-quarter numbers laid bare the depth of the trouble. Revenue landed at $2.26 billion, missing the consensus estimate of $2.31 billion, while adjusted earnings per share of $1.53 fell short of the $1.61 analysts had penciled in. The company now expects full-year adjusted EPS in a range of $6.85 to $7.00, down from a previous ceiling of $7.10. Revenue guidance was trimmed to a maximum of $9.96 billion.

A storm of headwinds

Zoetis attributed the weakness to a shift in behaviour among US pet owners, who are increasingly price-sensitive and postponing routine visits or opting out of premium treatments. That trend has amplified structural problems the company already faced: key blockbuster drugs such as Convenia and Cerenia are losing patent protection, opening the door for cheaper alternatives.

The competitive landscape is turning hostile. Rival Elanco Animal Health raised its own revenue forecast on the back of new products like Zenrelia and Credelio Quattro, which target Zoetis in the lucrative dermatology and parasiticide segments. Elanco’s shares surged in contrast to Zoetis’s plunge.

Wall Street and the courts react

Analysts wasted little time downgrading their expectations. JPMorgan slashed its price target from $190 to $130, while UBS cut its fair value estimate to $99. The consensus on the Street is shifting toward a hold rating.

The scale of the sell-off has also attracted legal attention. Ademi LLP is investigating potential securities fraud claims, pointing to a possible disconnect between management’s earlier messaging and the sudden downgrade. Notably, Univest Financial Corp had sold more than a third of its Zoetis stake late last year, suggesting some institutional investors may have anticipated the downturn.

Management fights back

Zoetis has responded with a cost-reduction programme and stepped-up direct-to-consumer marketing to encourage pet owners to visit clinics. The company is also investing in AI-powered diagnostic tools designed to deliver faster lab results, a bid to differentiate its services even as demand softens.

All eyes will be on the annual general meeting scheduled for 20 May, where the board must convince shareholders how it plans to defend market share in the US against a resurgent Elanco and a value-conscious client base. With the stock already down more than 34 percent year to date, the pressure to deliver a credible turnaround plan has never been higher.